Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation

American Heart Journal

Volumn 145, Issue 4, 2003, Pages 665-669

  Kim, Michael H ^a,e,f   Decena, Benigno F ^b   Bruckman, David ^c   Eagle, Kim A ^d  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f EVANSTON HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; CORONARY CARE UNIT; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INTERNATIONAL STANDARD UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 0037385488     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.8     Document Type: Article

References (12)

1. Kim MH, Morady F, Conlon B, et al. Prospective, randomized study of management strategies in new, uncomplicated atrial fibrillation in the emergency room [abstract]. Pacing Clin Electrophysiol 2001;24:711.
2. Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: heparin, a statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
3. Harenberg J, Weuster B, Pfitzer M, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemostas 1993;19(1 Suppl):116-21.
4. Harenberg J, Huhle G, Piazolo L, et al. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular weight heparin. Semin Thromb Hemostas 1997;23:167-72.
5. Roijer A, Eskilsson J, Olsson B. Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Eur Heart J 2000;21:837-47.
6. Murray RD, Shah A, Jasper SE, et al. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am Heart J 2000;139:e5.
7. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001;38:1-35.
8. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579-89S.
9. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001;37:691-704.
10. Camm AJ. Atrial fibrillation: is there a role for low-molecular-weight heparin? Clin Cardiol 2001;24(1 Suppl):115-9.
11. The Advisory Board Company (Cardiovascular Roundtable). Post-CABG atrial fibrillation: advanced strategies for prevention and efficient treatment. Washington, DC; 2000.
12. Nightingale SL. Appropriate use of low-molecular-weight heparins. JAMA 1993;270:1672.